Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Anlon HealthcareNSE:AHCL +1.26%23 Altman Z2-Score is 32.23 as of Aug. 17, 2026, which is 800% above its 10-year median of 3.58. GuruFocus rates NSE:AHCL with a GF Score™ of 23/100. The stock has 4 warning signs investors should review. Among 929 Drug Manufacturers companies, Anlon Healthcare ranks worse than 107642.52% on this metric.
Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.
Good Sign:
Anlon Healthcare has a Altman Z2-Score of 32.23, indicating it is in Safe Zones. This implies the Altman Z2-Score is strong.
The zones of discrimination were as such:
When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.
The historical rank and industry rank for Anlon Healthcare's Altman Z2-Score or its related term are showing as below:
During the past 5 years, Anlon Healthcare's highest Altman Z2-Score was 32.08. The lowest was 2.05. And the median was 3.58.
The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
Altman Z2-Score does not apply to financial companies.
Anlon Healthcare Altman Z2-Score Related Terms
Anlon Healthcare Altman Z2-Score Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Altman Z2-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Altman Z2-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Altman Z2-Score distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Altman Z2-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.
Anlon Healthcare's Altman Z2-Score for today is calculated with this formula:
Z
=
6.56
*
X1
+
3.26
*
X2
+
6.72
*
X3
+
1.05
*
X4_2
=
6.56
*
0.5367
+
3.26
*
0
+
6.72
*
3.9709
+
1.05
*
1.9319
=
32.23
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.
Anlon Healthcare (NSE:AHCL) has a Altman Z2-Score of 32.23 as of Aug. 17, 2026. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Anlon Healthcare and its competitors. This is 800% above median its historical median of 3.58. Over the past decade, Anlon Healthcare's Altman Z2-Score has ranged from 2.05 to 32.08. According to the industry distribution chart, Anlon Healthcare ranks #999999 out of 929 companies in the Drug Manufacturers industry.
Is Anlon Healthcare's Altman Z2-Score too high?
Anlon Healthcare's current Altman Z2-Score of 32.23 is 800% above median its 10-year median of 3.58. Over the past 10 years, this metric has ranged from a low of 2.05 to a high of 32.08. The Drug Manufacturers industry median Altman Z2-Score is 3.69. Anlon Healthcare's value of 32.23 is 773.4% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #999999 out of 929 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Anlon Healthcare has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Altman Z2-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #999999 out of 929 companies for Altman Z2-Score. This places Anlon Healthcare in the lower half of its industry. The industry median Altman Z2-Score is 3.69. Anlon Healthcare's value of 32.23 is 773.4% above this benchmark. Historically, Anlon Healthcare's own Altman Z2-Score has ranged from 2.05 to 32.08 over the past decade. While the company's 10-year median is 3.58 vs. the industry median of 3.69, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z2-Score for a Drug Manufacturers company?
The median Altman Z2-Score among Drug Manufacturers companies is 3.69, based on 929 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z2-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z2-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Altman Z2-Score of 32.23 is 773.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z2-Score mean?
A high Altman Z2-Score can signal that a stock is expensive relative to its fundamentals. Z2-Score is the Z-Score for non-manufacturing companies excluding property/financial companies, which measures a company's bankruptcy risk. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median Altman Z2-Score is 3.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Altman Z2-Score is 32.23, which is 800% above median its own 10-year median of 3.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Altman Z2-Score of 32.23. The current Altman Z2-Score is 32.23, which is 800% above median its 10-year median of 3.58 and 773.4% above the Drug Manufacturers industry median of 3.69. Anlon Healthcare's overall GF Score™ is 23/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z2-Score calculated?
Altman Z2-Score is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Altman Z2-Score is 32.23 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
23GF Score
Get the complete analysis for NSE:AHCL
Altman Z2-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
